CSIMarket
 


Progenics Pharmaceuticals Inc  (PGNX)
Other Ticker:  
 

Progenics Pharmaceuticals Inc's Quick Ratio

PGNX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2020, Quick Ratio deteriorated to 1.6 a new company low.

Within Major Pharmaceutical Preparations industry 340 other companies have achieved higher Quick Ratio than Progenics Pharmaceuticals Inc in first quarter 2020. While Quick Ratio total ranking in the first quarter 2020 has deteriorated compared to the prior quarter from 846 to 1468.

Explain Quick Ratio?
How much Cash & cash equivalents PGNX´s has?
What are PGNX´s Current Liabilities?


PGNX Quick Ratio (Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Current Liabilities Change -23.09 % -8.43 % 18.65 % 56.03 % 68.63 %
Y / Y Cash & cash equivalent Change -73.05 % -69.46 % -57.11 % -4.71 % 27.61 %
Quick Ratio MRQ 1.6 1.96 3.3 3.69 4.56
PGNX's Total Ranking # 1468 # 846 # 628 # 735 # 585
Seq. Current Liabilities Change -13.91 % 9.69 % -14.96 % -4.23 % 2.5 %
Seq. Cash & cash equivalent Change -29.77 % -34.8 % -23.97 % -22.6 % -20.41 %



Quick Ratio first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 341
Healthcare Sector # 588
Overall Market # 1468


Quick Ratio Statistics
High Average Low
22.96 8.98 1.6
(Mar 31 2014)   (Mar 31 2020)




Financial Statements
Progenics Pharmaceuticals Inc's Current Liabilities $ 18 Millions Visit PGNX's Balance sheet
Progenics Pharmaceuticals Inc's Cash & cash equivalent $ 30 Millions Visit PGNX's Balance sheet
Source of PGNX's Sales Visit PGNX's Sales by Geography


Cumulative Progenics Pharmaceuticals Inc's Quick Ratio

PGNX's Quick Ratio for the trailling 12 Months

PGNX Quick Ratio

(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Current Liabilities TTM Growth -23.09 % -8.43 % 18.65 % 56.03 % 68.63 %
Y / Y Cash & cash equivalent TTM Growth -73.05 % -69.46 % -57.11 % -4.71 % 27.61 %
Quick Ratio TTM 2.68 3.42 4.4 5.55 6.18
Total Ranking TTM # 903 # 717 # 558 # 474 # 414
Seq. Current Liabilities TTM Growth -13.91 % 9.69 % -14.96 % -4.23 % 2.5 %
Seq. Cash & cash equivalent TTM Growth -29.77 % -34.8 % -23.97 % -22.6 % -20.41 %


On the trailing twelve months basis In spite of the year on year decrease in PGNX's Current Liabilities to $18.48 millions, cumulative Quick Ratio to 2.68 below the PGNX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 484 other companies have achieved higher Quick Ratio than Progenics Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the forth quarter 2019 from 533 to 831.

Explain Quick Ratio?
How much Cash & cash equivalents PGNX´s has?
What are PGNX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 485
Healthcare Sector # 935
Within the Market # 1468


trailing twelve months Quick Ratio Statistics
High Average Low
19.81 9.1 2.6
(Mar 31 2015)   (Mar 31 2020)




Companies with similar Quick Ratio in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2020 MRQ Cash & cash equivalentMar 31 2020 MRQ Current Liabilities
Proqr Therapeutics N v   4.38 $ 84.939  Millions$ 19.403  Millions
Optinose Inc   4.34 $ 148.475  Millions$ 34.225  Millions
Chemomab Therapeutics Ltd   4.27 $ 14.009  Millions$ 3.283  Millions
Pieris Pharmaceuticals Inc   4.24 $ 86.764  Millions$ 20.483  Millions
China Health Industries Holdings Inc   4.19 $ 36.594  Millions$ 8.733  Millions
Orgenesis Inc   4.13 $ 107.069  Millions$ 25.910  Millions
Vascular Biogenics Ltd   4.08 $ 30.445  Millions$ 7.459  Millions
Amarin Corp Plcuk  4.04 $ 546.145  Millions$ 135.308  Millions
Cue Biopharma Inc   4.03 $ 48.730  Millions$ 12.090  Millions
Cormedix Inc   4.00 $ 23.208  Millions$ 5.804  Millions
Rezolute Inc   3.99 $ 14.068  Millions$ 3.530  Millions
Pacira Biosciences inc   3.97 $ 318.464  Millions$ 80.313  Millions
Acer Therapeutics Inc   3.94 $ 7.007  Millions$ 1.780  Millions
Spero Therapeutics Inc   3.91 $ 88.841  Millions$ 22.741  Millions
Alnylam Pharmaceuticals Inc   3.85 $ 1,304.125  Millions$ 338.791  Millions
Molecular Templates inc   3.84 $ 104.988  Millions$ 27.309  Millions
Lipocine Inc   3.84 $ 15.583  Millions$ 4.060  Millions
Nighthawk Biosciences inc   3.81 $ 26.445  Millions$ 6.937  Millions
Zentalis Pharmaceuticals Inc   3.76 $ 63.650  Millions$ 16.939  Millions
Qualigen Therapeutics Inc   3.72 $ 5.953  Millions$ 1.602  Millions
Intercept Pharmaceuticals inc   3.71 $ 555.680  Millions$ 149.968  Millions
Amicus Therapeutics inc   3.69 $ 338.873  Millions$ 91.714  Millions
Cara Therapeutics inc   3.69 $ 120.196  Millions$ 32.603  Millions
Heron Therapeutics Inc   3.68 $ 356.346  Millions$ 96.765  Millions
Rockwell Medical inc   3.66 $ 48.856  Millions$ 13.357  Millions
Purple Biotech Ltd   3.63 $ 11.247  Millions$ 3.098  Millions
Siga Technologies Inc  3.61 $ 77.377  Millions$ 21.425  Millions
Moleculin Biotech Inc   3.60 $ 11.649  Millions$ 3.235  Millions
Nektar Therapeutics  3.57 $ 1,345.882  Millions$ 377.471  Millions
Theriva Biologics inc   3.51 $ 10.100  Millions$ 2.876  Millions

Date modified: 2023-03-24T03:09:35+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com